Sumatra, Kimberly .
HRN: 22-74-67 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/13/2023
CO-AMOXICLAV 625MG (TAB)
03/13/2023
03/20/2023
PO
625 Mg
Every 8 Hours
Thickly Meconium-Stained Amniotic Fluid
Waiting Final Action
Indication: Prophylaxis Type of Infection: Prophylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes